Hjem › Kronisk myelomonocytisk leukæmi › Ohio
Kronisk myelomonocytisk leukæmi kliniske forsøg i Ohio
5 studier for Kronisk myelomonocytisk leukæmi søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. aug. 2026 · NCT06523556A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. mar. 2026 · NCT06543381Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2025 · NCT03850574Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.